Genscript Biotech Corporation
1548
주식 순위
#2098
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
주가
$4.37
시가총액
$9.84B
변동 (1일)
2.30%
변동 (1년)
109.57%
국가
HK
거래 Genscript Biotech Corporation (1548)
카테고리
Healthcare
Genscript Biotech Corporation (1548)의 P/E 비율
October 2026 기준 P/E 비율 TTM: -13.63
Genscript Biotech Corporation의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 -13.63입니다. 2023년 말 기준 P/E 비율은 -53.79였습니다.
Genscript Biotech Corporation의 P/E 비율 기록 (2013 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | -13.63 | -1,565.67% |
| 2024 | 0.93 | -101.73% |
| 2023 | -53.79 | 82.95% |
| 2022 | -29.40 | 17.43% |
| 2021 | -25.04 | 86.25% |
| 2020 | -13.44 | -69.05% |
| 2019 | -43.43 | -138.14% |
| 2018 | 113.88 | -35.88% |
| 2017 | 177.59 | 484.44% |
| 2016 | 30.39 | 161.99% |
| 2015 | 11.60 | -65.24% |
| 2014 | 33.37 | -26.47% |
| 2013 | 45.38 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -311.15% |
US
|
|
| -28.36 | 108.05% |
US
|
|
| -24.57 | 80.23% |
AU
|
|
| 30.33 | -322.51% |
NL
|
|
| - | - |
CH
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.